POTELIGEO achieved a higher response rate with a long duration of response (CR+PR) in blood^1-3

Response rate in blood (confirmed response)^a-c
(ad hoc analysis of secondary endpoint)

Duration of continued response (median)^d
(post hoc analysis)

In skin^b,e:

• POTELIGEO patients showed a 42% (n=78/186) response rate, compared to 15% in vorinostat patients (n=29/186) (ad hoc analysis of secondary endpoint)
• POTELIGEO patients (n=78) achieved a median 20.6-month duration of continued response, compared to 10.7 months in vorinostat patients (post hoc analysis)^d

In lymph nodes^f,g:

• POTELIGEO patients showed a 15% (n=21/136) response rate, compared to 3.7% in vorinostat patients (n=29/186) (ad hoc analysis of secondary endpoint)
• POTELIGEO patients (n=21) achieved a median 15-month duration of continued response; vorinostat patients were not estimable (post hoc analysis)^d

In viscera^f:

• No response was observed in viscera in either treatment group (POTELIGEO 0% [n=6]; vorinostat 0% [n=4])

• ^aResponse was defined by international response criteria for Mycosis Fungoides and Sézary Syndrome.⁴
• ^bResponses in blood and skin must have persisted for ≥4 weeks to be confirmed and were evaluated every 4 weeks during treatment.^1,5
• ^cResponse in blood defined as >50% decrease in high blood tumor burden (B2), assessed by central flow cytometry.⁵
• ^d Duration of response was measured based on a post hoc analysis; a finding from the post hoc analysis cannot be used to demonstrate differences between treatments and may not be applicable to all patients initiating POTELIGEO.
• ^eResponse in skin defined as ≥50% clearance of skin disease without new tumors, evaluated using the modified Severity Weighted Assessment Tool (mSWAT).⁵
• ^fResponses in lymph nodes and viscera were evaluated at 4 weeks, then every 8 weeks for the first year, and every 16 weeks thereafter.²
• ^gResponses in lymph nodes defined as cumulative reduction ≥50% of measurable disease of each abnormal lymph node and no new abnormal lymph nodes, evaluated by computed tomography (CT) scans.⁵
• CR=complete response; PR=partial response

POTELIGEO was evaluated in the largest randomized, open-label, phase 3 trial of a systemic therapy for patients with Mycosis Fungoides and Sézary Syndrome^1,2,6

Expand for
Study Design

372 patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS) were evaluated across Stage IB-IV for progression-free survival (PFS) as well as overall response rate (ORR) and duration of response (DoR) in multiple disease compartments (skin, blood, lymph nodes, viscera).

MAVORIC

Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL

The MAVORIC trial included a broad range of patients^1-3

BLOOD CLASSIFICATION^5,7

• (n=64)

• <15%
  CD4+CD26- or CD4+CD7- cells by flow cytometry

• (n=31)
• ≥15%
  CD4+CD26- or CD4+CD7- cells by flow cytometry

• (n=91)

• ≥1000/μL Sézary cells with positive clone
  or 1 of the following:

  • CD4:CD8 ratio ≥10,
  • 40% CD4+CD7- cells, or
  • ≥30% CD4+CD26- cells

Patient characteristics1,3
Age (years)
Age (years)	Median, 64	Min, 25	Max, 101
Sex
Sex	Males, 58%	Females, 42%
Race
Race	White, 70%	African American, 13%	Asian, 7%	Other, 10% (Not reported)
Prior systemic therapies
Prior systemic therapies	Median, 3	Min, 0	Max, 18

Key exclusion criteria⁵

• Large cell transformation at study entry
• Active autoimmune diseases
• CNS metastasis

• Active infection requiring therapy
• Medical conditions requiring systemic corticosteroids or other immunosuppressive medication

CNS=central nervous system; CTCL=cutaneous T-cell lymphoma; PO=by mouth; R/R=relapsed or refractory